

Publications Prof. Kristian Reich, MD, PhD

2021

1. [Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment \(UPLIFT\) Survey.](#)
Lebwohl M, Langley RG, Paul C, Puig L, **Reich K**, van de Kerkhof P, Wu HL, Richter S, Jardon S, Gisondi P.
Dermatol Ther (Heidelb). 2022 Jan 6. doi: 10.1007/s13555-021-00656-z.
Online ahead of print.
PMID: 34989998 No abstract available.
2. [Secukinumab dosing every two weeks demonstrated superior efficacy compared with dosing every four weeks in patients with psoriasis weighing 90 kg or more: Results of a randomised controlled trial.](#)
Augustin M, **Reich K**, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D.
Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20971. Online ahead of print.
PMID: 34981829
3. [Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany.](#)
Tizek L, Schuster B, Gebhardt C, **Reich K**, von Kiedrowski R, Biedermann T, Eyerich K, Zink A, Garzorz-Stark N.
J Dtsch Dermatol Ges. 2021 Dec 28. doi: 10.1111/ddg.14659. Online ahead of print.
PMID: 34962069
4. [Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.](#)
Reich K, Korge B, Magnolo N, Manasterski M, Schwichtenberg U, Staubach-Renz P, Kaiser S, Roemmler-Zehrer J, Gómez NN, Lorenz-Baath K.
Dermatol Ther (Heidelb). 2021 Dec 15. doi: 10.1007/s13555-021-00658-x.
Online ahead of print.
PMID: 34913153
5. [Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis.](#)
Conrad C, Ortman CE, Vandemeulebroecke M, Kasperek T, **Reich K**.
Dermatol Ther (Heidelb). 2021 Dec 6. doi: 10.1007/s13555-021-00654-1.
Online ahead of print.
PMID: 34870789
6. [Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?](#)

- Kirsten N, Rustenbach S, von Kiedrowski R, Sorbe C, **Reich K**, Augustin M. Life (Basel). 2021 Oct 28;11(11):1151. doi: 10.3390/life11111151. PMID: 34833027 **Free PMC article.**
7. [Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment \(UPLIFT\) Survey.](#)
Lebwohl M, Langley RG, Paul C, Puíg L, **Reich K**, van de Kerkhof P, Wu HL, Richter S, Jardon S, Gisondi P.
Dermatol Ther (Heidelb). 2021 Oct 25;1-16. doi: 10.1007/s13555-021-00635-4. Online ahead of print.
PMID: 34704231 **Free PMC article.**
 8. [Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis.](#)
Silverberg JI, Simpson EL, Armstrong AW, de Bruin-Weller MS, Irvine AD, **Reich K**.
Am J Clin Dermatol. 2021 Oct 26. doi: 10.1007/s40257-021-00639-y. Online ahead of print.
PMID: 34699031
 9. [Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.](#)
Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhal R, **Reich K**.
Br J Dermatol. 2021 Oct 15. doi: 10.1111/bjd.20818. Online ahead of print.
PMID: 34652810
 10. [The hair follicle-psoriasis axis: Shared regulatory mechanisms and therapeutic targets.](#)
Suzuki T, Ito T, Gilhar A, Tokura Y, **Reich K**, Paus R.
Exp Dermatol. 2021 Sep 29. doi: 10.1111/exd.14462. Online ahead of print.
PMID: 34587317 Review.
 11. [Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.](#)
Fahrbach K, Sarri G, Phillippo DM, Neupane B, Martel SE, Kiri S, **Reich K**.
Dermatol Ther (Heidelb). 2021 Dec;11(6):1965-1998. doi: 10.1007/s13555-021-00602-z. Epub 2021 Sep 22.
PMID: 34549383 **Free PMC article.**
 12. [IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis \(GUIDE\).](#)
Eyerich K, Weisenseel P, Pinter A, Schäkel K, Asadullah K, Wegner S, Muñoz-Elias EJ, Bartz H, Taut FJH, **Reich K**.
BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822.
PMID: 34518264 **Free PMC article.**

13. [Network meta-analyses in psoriasis: overview and critical discussion.](#)
Augustin M, Valencia López M, **Reich K**.
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2367-2376. doi:
10.1111/jdv.17650. Epub 2021 Sep 24.
PMID: 34506643 Review.
14. [Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.](#)
Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, Kabashima K,
Costanzo A, Rosmarin D, Lynde C, Liu J, Gamelli A, Zeng J, Ladizinski B,
Chu AD, **Reich K**.
J Allergy Clin Immunol. 2021 Aug 14:S0091-6749(21)01212-4. doi:
10.1016/j.jaci.2021.07.036. Online ahead of print.
PMID: 34403658
15. [Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.](#)
Foley P, **Reich K**, Blauvelt A, Bagel J, Langley RG, Miller M,
Ramachandran P, Yang YW, Shen YK, You Y, Lebwohl M, Griffiths CEM.
J Drugs Dermatol. 2021 Aug 1;20(8):855-860. doi: 10.36849/JDD.6216.
PMID: 34397205 Clinical Trial.
16. [Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.](#)
Blauvelt A, Armstrong AW, Langley RG, Gebauer K, Taçi D, Bagel J,
Guenther LC, Paul C, Randazzo B, Flavin S, Hsu MC, You Y, **Reich K**.
J Dermatolog Treat. 2021 Aug 4:1-8. doi: 10.1080/09546634.2021.1959504.
Online ahead of print.
PMID: 34348574
17. [Transcriptomic Analysis of Blaschko-Linear Psoriasis Reveals Shared and Distinct Features with Psoriasis Vulgaris.](#)
Onoufriadis A, Niazi U, Dimitrakopoulou K, Reich J, Ainali C, Papanikolaou
M, Kesidou E, Hsu CK, Saqi M, McGrath JA, **Reich K**.
J Invest Dermatol. 2021 Jul 24:S0022-202X(21)01506-2. doi:
10.1016/j.jid.2021.07.007. Online ahead of print.
PMID: 34310949 No abstract available.
18. [German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations.](#)
Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J,
Mrowietz U, Ockenfels HM, Philipp S, **Reich K**, Rosenbach T, Schlaeger M,
Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C.
J Dtsch Dermatol Ges. 2021 Jul;19(7):1092-1115. doi: 10.1111/ddg.14507.
PMID: 34288477 No abstract available.
19. [Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität.](#)

- Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, **Reich K**, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. *J Dtsch Dermatol Ges.* 2021 Jul;19(7):1092-1117. doi: 10.1111/ddg.14507_g. PMID: 34288473 No abstract available.
20. [Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.](#)
Reich K, Mrowietz U, Menter A, Griffiths CEM, Bagel J, Strober B, Nunez Gomez N, Shi R, Guerette B, Lebwohl M.
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2409-2414. doi: 10.1111/jdv.17520. Epub 2021 Aug 23.
PMID: 34255891
21. [German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations.](#)
Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, **Reich K**, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. *J Dtsch Dermatol Ges.* 2021 Jun;19(6):934-150. doi: 10.1111/ddg.14508. PMID: 34139083 No abstract available.
22. [Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 1: Therapieziele und Therapieempfehlungen.](#)
Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, **Reich K**, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. *J Dtsch Dermatol Ges.* 2021 Jun;19(6):934-951. doi: 10.1111/ddg.14508_g. PMID: 34139080 German. No abstract available.
23. [Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.](#)
Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM.
Br J Dermatol. 2021 Dec;185(6):1146-1159. doi: 10.1111/bjd.20568. Epub 2021 Sep 8.
PMID: 34105767
24. [A multicentre open-label study of apremilast in palmoplantar pustulosis \(APLANTUS\).](#)
Wilsmann-Theis D, Kromer C, Gerdes S, Linker C, Magnolo N, Sabat R, **Reich K**, Mössner R.
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):2045-2050. doi: 10.1111/jdv.17441. Epub 2021 Jun 24.
PMID: 34077577 Clinical Trial.
25. [Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.](#)
Reich K, Hansen JB, Puig L, Konstantinou MP, Warren RB.

- J Eur Acad Dermatol Venereol. 2021 Oct;35(10):2034-2044. doi: 10.1111/jdv.17433. Epub 2021 Jul 24.
PMID: 34076919 Clinical Trial.
26. [Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis \(AD Up\): results from a randomised, double-blind, placebo-controlled, phase 3 trial.](#)
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI.
Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.
PMID: 34023009 Clinical Trial.
27. [Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.](#)
Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, Sun L, Cardillo T, Nunes FP, **Reich K**.
JAMA Dermatol. 2021 Jun 1;157(6):691-699. doi: 10.1001/jamadermatol.2021.1273.
PMID: 33978711 **Free PMC article.**
28. [Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.](#)
Gottlieb AB, Merola JF, **Reich K**, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB.
Br J Dermatol. 2021 Dec;185(6):1124-1134. doi: 10.1111/bjd.20413. Epub 2021 Jul 14.
PMID: 33913511
29. [IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.](#)
Papp KA, Weinberg MA, Morris A, **Reich K**.
Lancet. 2021 Apr 24;397(10284):1564-1575. doi: 10.1016/S0140-6736(21)00440-2.
PMID: 33894834 Clinical Trial.
30. [Bimekizumab versus Secukinumab in Plaque Psoriasis.](#)
Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A.
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383.
Epub 2021 Apr 23.

- PMID: 33891380 Clinical Trial.
31. [Bimekizumab versus Adalimumab in Plaque Psoriasis.](#)
Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, **Reich K**.
N Engl J Med. 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23.
PMID: 33891379 Clinical Trial.
 32. [Patch test results in patients with suspected contact allergy to shoes: Retrospective IVDK data analysis 2009-2018.](#)
Traidl S, Werfel T, Ruëff F, Simon D, Lang C, Geier J; IVDK.
Contact Dermatitis. 2021 Sep;85(3):297-306. doi: 10.1111/cod.13868. Epub 2021 May 11.
PMID: 33882155
 33. [Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.](#)
Maul JT, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U, **Reich K**, French LE, Radtke M, Häusermann P, Maul LV, Boehncke WH, Thaçi D, Navarini AA.
Br J Dermatol. 2021 Dec;185(6):1160-1168. doi: 10.1111/bjd.20387. Epub 2021 Jun 22.
PMID: 33837519
 34. [Quality of psoriasis care in Germany - results from the nationwide health care studies PsoHealth 2004-2017.](#)
Langenbruch A, Mohr N, Kirsten N, **Reich K**, von Kiedrowski R, Strömer K, Mrowietz U, Augustin M.
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1536-1542. doi: 10.1111/jdv.17220. Epub 2021 May 7.
PMID: 33714231
 35. [Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.](#)
Mrowietz U, Burden AD, Pinter A, **Reich K**, Schäkel K, Baum P, Datsenko Y, Deng H, Padula SJ, Thoma C, Bissonnette R.
Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585. doi: 10.1007/s13555-021-00504-0. Epub 2021 Mar 4.
PMID: 33661508 **Free PMC article.**
 36. [Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.](#)
Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, Rich P, Sapin C, Holzkaemper T, Koppelhus U, Schuster C.
J Dermatolog Treat. 2021 Mar 1:1-9. doi: 10.1080/09546634.2021.1892024. Online ahead of print.

PMID: 33641593

37. [Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis \(BE VIVID\): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.](#)
Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M.
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
PMID: 33549193 Clinical Trial.
38. [Bimekizumab efficacy and safety in moderate to severe plaque psoriasis \(BE READY\): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.](#)
Gordon KB, Foley P, Krueger JG, Pinter A, **Reich K**, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A.
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.
PMID: 33549192 Clinical Trial.
39. [EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.](#)
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul JT, Mburu S, Mrowietz U, **Reich K**, Remenyik E, Rønholt KM, Sator PG, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigoso D, Van Der Kraaij G, Yawalkar N, Dressler C.
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):281-317. doi: 10.1111/jdv.16926.
PMID: 33547728
40. [Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials \(reSURFACE 1 and reSURFACE 2\).](#)
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, **Reich K**.
Br J Dermatol. 2021 Aug;185(2):323-334. doi: 10.1111/bjd.19866. Epub 2021 May 4.
PMID: 33544883 Clinical Trial.
41. [Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab.](#)
Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YM, Maari C, **Reich K**, Blauvelt A, Bissonnette R, Muñoz-Elías EJ, Sarfati M.
J Invest Dermatol. 2021 Jul;141(7):1707-1718.e9. doi: 10.1016/j.jid.2021.01.005. Epub 2021 Jan 30.

- PMID: 33524368 Clinical Trial.
42. [Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values \$\leq 1, 2, 3\$ or 5 derived from a statistical conversion method.](#)
Mrowietz U, Warren RB, Leonardi CL, Saure D, Petto H, Hartz S, Dossentach M, **Reich K**.
J Eur Acad Dermatol Venereol. 2021 May;35(5):1161-1175. doi: 10.1111/jdv.17130. Epub 2021 Feb 15.
PMID: 33480102 **Free PMC article**.
 43. [Mouse models of atopic dermatitis: a critical reappraisal.](#)
Gilhar A, **Reich K**, Keren A, Kabashima K, Steinhoff M, Paus R.
Exp Dermatol. 2021 Mar;30(3):319-336. doi: 10.1111/exd.14270. Epub 2021 Jan 9.
PMID: 33368555
 44. [The value of subcutaneous vs. oral methotrexate: real-world data from the German psoriasis registry PsoBest.](#)
Reich K, Sorbe C, Griese L, Reich JLK, Augustin M.
Br J Dermatol. 2021 Apr;184(4):765-767. doi: 10.1111/bjd.19690. Epub 2020 Dec 30.
PMID: 33220078 No abstract available.
 45. [Psychosocial functioning in veterans with combat-related PTSD: An evolutionary concept analysis.](#)
Reich K, Nemeth LS, Mueller M, Sternke LM, Acierno R.
Nurs Forum. 2021 Jan;56(1):194-201. doi: 10.1111/nuf.12519. Epub 2020 Oct 30.
PMID: 33125741
 46. [Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach.](#)
Tsakok T, Rispens T, Spuls P, Nast A, Smith C, **Reich K**.
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):329-337. doi: 10.1111/jdv.16980. Epub 2021 Jan 1.
PMID: 33030275 Review.
 47. [Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.](#)
Warren RB, Carrascosa JM, Fumero E, Schoenenberger A, Lebwohl MG, Szepletowski JC, **Reich K**.
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):919-927. doi: 10.1111/jdv.16964. Epub 2020 Nov 5.
PMID: 32979235 Clinical Trial.
 48. [Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.](#)

- Leutz A, Pinter A, Thaçi D, Augustin M, Schuster C, Fotiou K, Hundemer HP, Saure D, Mrowietz U, **Reich K**.
Br J Dermatol. 2021 Mar;184(3):548-550. doi: 10.1111/bjd.19558. Epub 2020 Nov 10.
PMID: 32940343 No abstract available.
49. [A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis \(CHANGE\).](#)
Pinter A, Hoffmann M, **Reich K**, Augustin M, Kaplan K, Gudjónsdóttir SD, Delvin T, Mrowietz U; CHANGE investigator group.
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):701-711. doi: 10.1111/jdv.16932. Epub 2020 Dec 23.
PMID: 32939860 Clinical Trial.
50. [Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.](#)
Bieber T, Thyssen JP, **Reich K**, Simpson EL, Katoh N, Torrelo A, De Bruin-Weller M, Thaci D, Bissonnette R, Gooderham M, Weisman J, Nunes F, Brinker D, Issa M, Holzwarth K, Gamalo M, Riedl E, Janes J.
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):476-485. doi: 10.1111/jdv.16948. Epub 2020 Oct 6.
PMID: 32926462
51. [The vertical course of bone regeneration in maxillary sinus floor augmentations: A histomorphometric analysis of human biopsies.](#)
Beck F, **Reich KM**, Lettner S, Heimel P, Tangl S, Redl H, Ulm C.
J Periodontol. 2021 Feb;92(2):263-272. doi: 10.1002/JPER.19-0656. Epub 2020 Aug 19.
PMID: 32715479 **Free PMC article.**
52. [Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.](#)
Warren RB, Hansen JB, **Reich K**, Paul C, Puig L.
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):450-457. doi: 10.1111/jdv.16816. Epub 2020 Aug 26.
PMID: 32662540 Clinical Trial.
53. [Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials \(CIMPASI-1 and CIMPASI-2\).](#)
Gordon KB, Warren RB, Gottlieb AB, Blauvelt A, Thaçi D, Leonardi C, Poulin Y, Boehnlein M, Brock F, Ecoffet C, **Reich K**.
Br J Dermatol. 2021 Apr;184(4):652-662. doi: 10.1111/bjd.19393. Epub 2020 Sep 9.
PMID: 32652544 **Free PMC article.** Clinical Trial.
54. [Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.](#)
Reich K, Körber A, Mrowietz U, Sticherling M, Sieder C, Früh J, Bachhuber T.

Br J Dermatol. 2021 May;184(5):849-856. doi: 10.1111/bjd.19398. Epub 2020 Nov 18.
PMID: 32652528 Clinical Trial.

55. [Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.](#)
Blauvelt A, Paul C, van de Kerkhof P, Warren RB, Gottlieb AB, Langley RG, Brock F, Arendt C, Boehnlein M, Lebwohl M, **Reich K**.
Br J Dermatol. 2021 Apr;184(4):640-651. doi: 10.1111/bjd.19314. Epub 2020 Sep 6.
PMID: 32531798 **Free PMC article**.
56. [Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.](#)
Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, Elewski B, You R, Regnault P, Frueh JA.
Br J Dermatol. 2021 Mar;184(3):425-436. doi: 10.1111/bjd.19262. Epub 2020 Dec 16.
PMID: 32479641 Clinical Trial.